Nicht aus der Schweiz? Besuchen Sie lehmanns.de
COVID-19 and the Cardiovascular System -

COVID-19 and the Cardiovascular System

From Pathophysiology to Clinical Management

Brian C. Case, Ron Waksman (Herausgeber)

Buch | Softcover
342 Seiten
2024
Academic Press Inc (Verlag)
978-0-443-14001-3 (ISBN)
CHF 219,95 inkl. MwSt
  • Versand in 15-20 Tagen
  • Versandkostenfrei
  • Auch auf Rechnung
  • Artikel merken
COVID-19 and the Cardiovascular System: From Pathophysiology to Clinical Management comprehensively covers COVID-19’s impact on the cardiovascular system. Coverage includes the pathophysiology, clinical manifestations, diagnostic approach, treatment options, and clinical outcomes of patients presenting with COVID-19 with cardiac involvement. In a concise but comprehensive manner, the book's content reviews the epidemiology, risk factors, pathophysiology of COVID-19, cardiovascular clinical manifestations, non-invasive and invasive diagnostic evaluation, therapeutic options, outcomes data, role of the COVID-19 vaccine, and long-term outcomes/management.

This is the perfect reference for basic and clinical researchers in cardiovascular medicine as well as practicing clinical cardiologists who are dealing with COVID-19 patients with cardiac involvement.

Brian Case, MD, FACC, FSACI is an Interventional Cardiologist at MedStar Heart and Vascular Institute, working at MedStar Washington Hospital Center, MedStar Georgetown University Hospital and MedStar Southern Maryland Hospital. He is the Chief of Interventional Cardiology and Director of the Cardiac Cath Lab at MedStar Southern Maryland Hospital. He holds an appointment of Assistant Professor of Medicine, Georgetown University. He is board certified in interventional cardiology, cardiovascular disease and internal medicine with extensive fellowship training. He is also an associate editor of the Cardiovascular Revascularization Medicine Journal. He has as written over ten first author manuscripts on original data evaluating the impact of the COVID-19 on the cardiovascular system. This includes clinical outcomes, therapeutic options, and the role of the COVID-19 vaccine on outcomes. He has also written several editorials and review papers on the topic. His work has been presented at multiple national cardiology conference. His healthcare center (MedStar) has been a contributing site to the North American COVID-19 Myocardial infarction Registry, which is a national, multi-site registry evaluating patients with COVID-19 presenting with ST-elevation myocardial infarction. The registry has already published multiple manuscripts with plans to continue this work. Ron Waksman, MD, FACC, FESC, MSCAI, is a distinguished Professor of Cardiology at Georgetown University, Associate Director of Cardiology at MedStar Washington Hospital Center, and Director of Cardiovascular Research and Advanced Education at MedStar Health. A globally recognized interventional cardiologist, he has been Principal Investigator for over 230 clinical studies. He is Editor-in-Chief of the Journal Cardiovascular, Revascularization Medicine, and is founder and chair of the Cardiovascular Research Technology meeting. He is credited on 15 patents in vascular brachytherapy, covered stents, leaflet valve modification, and balloon technology. His research interests include brachytherapy for restenosis prevention, stent technology, biodegradable scaffolds, HDL therapy, vulnerable plaque, intracoronary imaging, structural heart disease, cardiovascular pharmacotherapy, and chronic total occlusion intervention. Dr. Waksman's scholarly contributions include over 1000 published manuscripts, over 16 edited textbooks, and 47 book chapters. He is also founder and Editor-in-Chief of the CRTonline and the CardioTube websites.

1. Foreword
2. Introduction/Epidemiology
3. Pathophysiology of COVID-19
4. Risk Factors/Special Populations
5. Pathophysiology of COVID-19 and the Heart
6. Cardiac Clinical Manifestation
7. Non-Invasive Diagnostic Evaluation
8. Invasive Diagnostic Evaluation
9. Acute and Long-Term Treatment Options
10. Acute Clinical Outcome/Prognosis
11. Long Term Clinical Outcomes/Prognosis
12. Impact of COVID-19 on Heart Failure Patients and Valvular Heart Patients.
13. Emerging Therapeutic Options
14. The Role of COVID-19 Vaccine
15. Prologue

Erscheinungsdatum
Verlagsort San Diego
Sprache englisch
Maße 191 x 235 mm
Gewicht 450 g
Themenwelt Medizinische Fachgebiete Innere Medizin Kardiologie / Angiologie
Studium 2. Studienabschnitt (Klinik) Pathologie
Studium Querschnittsbereiche Epidemiologie / Med. Biometrie
Naturwissenschaften Biologie
ISBN-10 0-443-14001-4 / 0443140014
ISBN-13 978-0-443-14001-3 / 9780443140013
Zustand Neuware
Informationen gemäß Produktsicherheitsverordnung (GPSR)
Haben Sie eine Frage zum Produkt?
Mehr entdecken
aus dem Bereich
in Fällen, Fragen und Antworten

von Christoph Spes; Volker Klauss; Sibylle Tönjes

Buch | Softcover (2024)
Urban & Fischer in Elsevier (Verlag)
CHF 124,60
Diagnostik und interventionelle Therapie | 2 Bände

von Raimund Erbel; Michael Haude; Philipp Kahlert; Björn Plicht …

Buch (2024)
Deutscher Ärzteverlag
CHF 489,95

von Julia Christ

Buch | Softcover (2022)
Urban & Fischer in Elsevier (Verlag)
CHF 37,80